The World Biotech Market 2005 Questions
Pages: 262
Price (Single): £4,999
Price (Departmental): £9,999
Price (Company): £14,999
Publication Date: 2005-06-17
People that purchased this report also purchased:
Contact LeadDiscovery
If you have questions about this report To find out if you qualify for a discount Want a more up to date version Can't find a report that meets your needs Search all reports
The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science driven by the 2001 human genome project is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis to multiple sclerosis and orphan diseases such as Fabry's disease.
Visiongain values the 2005 biopharma market at $70.8bn. Having grown 16.5% from 2004's revenues of $60.7bn, double-digit growth of the market will continue to the end of the decade. Composed of 9 major therapeutic areas including oncology, anti-infectives, vaccines and the market leader blood disorders, the market by 2010 is expected to represent 17% of all prescriptions written compared with 2004's 12%. At this pace of growth, biotech is now outgrowing Big Pharma.
Biotech companies however still face major challenges. The threat of the emergence of biogenerics is mounting, with 11 products facing patent expiry before 2007- 5 of which are blockbusters. The Australian approval of his Sandoz's Omnitrope hGH product is paving the way, and increasing pressure upon EU and US regulatory agencies to give the go ahead to biogenerics.
1. Executive Summary of the World Biotech Market
The report provides in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena
Why You Must Buy This Report?
This 262 paged report spanning 15 chapters features over 80 tables, 85 graphs and charts, news, insights and the latest developments. Over 120 companies are mentioned in this up-to-date report, which reviews 2004 revenues for all the biopharmaceutical products featured within the market.
Table of Contents
Chapter 1: Executive Summary of World Biotech Market, 2005
1.1 Abstract of Biotech, 2005
1.2 Aims, Scope and Format of Biotech, 2005
Chapter 2: Introduction to Biotechnology
2.1 What is Biotechnology?
2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around
2.3 Biotechnologies Used and Their Applications to Pharma
2.3.1 Bioprocessing Technology
2.3.2 Monoclonal Antibodies
2.3.3 Recombinant DNA Technology
2.3.4 Cloning
2.3.4.1 Molecular Cloning
2.3.4.2 Cellular Cloning
2.3.4.3 Animal Cloning
2.3.4.4 Protein Engineering
2.4 The Future Biopharmaceutical Market
2.4.1 Biopharmaceutical 2004 Market Capatilisation Worth $311bn
2.4.2 Over 7000 Biotechnology Patents Granted Per Annum Since 1998
2.4.3 2004 Witnessed 54 New Biopharmaceutical FDA Approvals
2.4.4 Biopharmaceuticals Share 12.5% of 2004 Global Prescriptions
Chapter 3: Diseases Treated by Biopharmaceuticals
3.1 Biopharmaceuticals Are Versatile Agents
3.2 Orphan Diseases Are A Major Target of Biotech: 3 Out of 10 2004 Orphan Disease Approvals Were Biopharmaceuticals
3.3 Overview to Major and Orphan Diseases Treated by Biopharmaceuticals, 2005
Chapter 4: Overview of Biopharmaceuticals Market, 2003-2004
4.1 Monoclonal Antibodies: Leading Class of Biopharmaceuticals in 2004 With Sales of $13bn
4.2 Blood Disorders Share Over A Quarter of 2004 Biopharmaceuticals Market
4.3 Biopharmaceuticals 2004 Market Worth a Staggering $55.7bn
4.4 The Top 20 Selling Biologics of 2004 Accounted For 62% of Total Revenues
4.5 Top 3 Biopharmaceuticals Products of 2004 Sold Over $9bn
4.5.1 Procrit/Eprex - The Number One Biopharmaceutical Struggles at the Top
4.5.2 Risperdal Performs Well Thanks to New Delivery Technology
4.5.3 Epogen: The Third Best Selling Biopharmaceutical of 2004
4.6 Santura: The Highest Earning Newcomer of 2004
Chapter 5: Company Revenues and Market Share, 2004
5.1 Amgen: The Reign Continues With A 17% Share of 2004 Market
5.2 Biotech Company Winners and Losers in 2004
5.3 BMS: The Best Company Newcomer of 2004
Chapter 6: Biopharmaceutical Pipeline
6.1 Technology Driving Biopharma Pipeline
6.2 Biotech Targeting Chronic Illness
6.3 Arthritis Biopharmaceutical Pipeline, 2005
6.4 MS Biopharmaceutical Pipeline, 2005
6.5 Late-Stage Biopharmaceutical Oncology Pipeline, 2005
6.6 Late Stage Biopharmaceutical Vaccine Pipeline, 2005
6.7 Blood Disorders Biopharmaceutical Pipeline, 2005
6.8 Late Stage Biopharmaceutical Endocrine Pipeline, 2005
6.9 Anti-Infectives Biopharmaceutical Pipeline, 2005
6.10 Enzyme Deficiency Biopharmaceutical Pipeline, 2005
6.11 Late Stage Biopharmaceutical Ophthalmic Pipeline, 2005
6.12 Late Stage Biopharmaceutical 'Other' Pipeline, 2005
Chapter 7: Biopharmaceutical Market Forecast by Therapeutic Area, 2003-2010
7.1 Blood Disorders
7.2 Endocrine Disorders
7.3 Multiple Sclerosis
7.4 Oncology
7.5 Anti Infectives
7.6 Enzyme Deficiency Disorders
7.7 Vaccines
7.8 Arthritis
7.9 Ophthalmics
7.10 Others
7.11 Biopharmaceutical Market Set To Almost Triple By 2010
Chapter 8: Summary of 2010 Biopharmaceuticals Market
8.1 Aransep: The Top Selling Biopharmaceutical of 2010 With Sales of $5.2bn
8.2 Blood Disorders Will Remain Market Leaders
8.3 Ophthalmic Biopharmaceuticals: The Fastest Growing Therapeutic Class 2003-2010
8.4 By 2010 Biopharmaceuticals Will Account for Over 17% of All Drug Prescriptions
Chapter 9: Introduction to Biogenerics
9.1 What are Biogenerics?
9.2 The Biogeneric Threat Looms Large
9.3 All Change in 2003: CDER to CBER
9.4 How are Approval Pathways Limiting the Development of Biogenerics?
9.5 Omnitrope Approved in Australia, Will Europe and the US Follow?
9.6 High Cost of Market Entry
9.7 Manufacturing Capacity Problems
9.8 Biopharma Vs Biogenerics: The Fight Continues
9.8.1 Bioequivalence or Biosimilarity?
9.9 Will the Benefits of Biogenerics be as Great as Anticipated?
9.10 How Imminent is the Threat from Biogeneric Competition?
Chapter 10: The Potential Biogeneric Market
10.1 $13bn of Biopharmaceuticals To Lose Patency Protection By 2007
10.2 Eleven Biopharmaceuticals to Face Patent Expiry by 2007
10.3 High-Revenue Generating Biopharmaceuticals Face Patent Expiry Before 2007
10.4 High-Profile Biopharmaceuticals With Patent Expirations Before 2007 Revenue Forecast, 2003-2010
10.5 Erythropoiteins Are Most At Risk To Biogeneric Competition
Chapter 11: Biopharmaceutical Market Challenges
11.1 BioTech's Delivery Challenge
11.1.1 Pulmonary Delivery: An Innovative Alternative to the Needle?
11.1.2 The Major Issues of the Pulmonary Pathway
11.1.3 Does Protein Formulation Affect Pulmonary Delivery?
11.1.4 Does Pulmonary Drug Delivery Have a Future?
11.1.5 Pegylated Forms Set to Revolutionise Delivery
11.1.6 Pegylation Can Extend Patencies! The Filgrastim Example
11.1.7 Transdermal Technologies
11.1.8 Microneedles for Transdermal Delivery of Vaccines
11.1.9 Nasal Delivery Is Demonstrating Promise
11.1.10 Moving Towards Pills? Altus' Unique Technology
11.1.11 New Delivery Technologies: A Pharmacy or Medical Benefit?
11.1.12 Innovative Insulin Delivery Technology: The Race is On!
11.1.13 Numerous Potential Blockbusting NonInjected Insulins Set to Arrive 2005-2009
11.2 Manufacturing Capacity Shortfall
11.2.1 Why is There a Shortfall in Manufacturing Capacity for Biopharmaceuticals?
11.2.2 Make Vs. Buy: The 1980s BioIndustry
11.2.3 CMO Manufacturing Capacity was Adequate for the Supply of Clinical Materials Only
11.2.4 Late-Stage Products have absorbed CMO Clinical Manufacturing Capacity
11.2.5 How is the Manufacturing Capacity Shortfall Being Overcome?
11.2.6 Does the Future for Biopharmaceutical Manufacturing Lie with Transgenics?
11.3 The Cost of Biopharmaceuticals
11.3.1 The Top Five Biopharmaceuticals Each cost at Least $10K Per Patient Per Annum
11.3.2 Monoclonal Antibodies and CSF's High Costs Reflect Production Difficulties
11.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in the Future
11.4 Acquiring Capital
11.4.1 Financing of Biotech Companies in 2003 Neared $17bn
11.5 Reliance Upon University/Company Collaborations
11.5.1 The Need For Collaboration
11.5.2 Biotech's Increasing Role of Commercialising University Research
11.5.3 Future Biotech Innovation Lies With Academia
11.5.4 The Risky Path from Bench to Market
11.5.5 Collaboration Strategies & Becoming the Partner of Choice
11.5.5.1 Objectives That Support Strategic Goals
11.5.5.2 Understanding the Value Brought to an Alliance
11.5.5.3 Identifying and Understanding Potential Partners
11.5.5.4 Due Diligence
11.5.5.5 Promoting Capabilities to Potential Partners
11.5.5.6 Maintaining a Relationship Through Structured Interactions
11.5.5.7 Gaining Competitive Advantage
11.5.5.8 Collaboration Management: Developing and Maintain A Deal
11.5.5.9 Strategic Goals to Consider
11.6 Regulatory Issues
11.6.1 Biopharmaceuticals and the FDA
11.6.2 FDA Improving Upon Biologics Approval Wait
11.7 Biogeneric Threat
11.8 Dependence upon Venture Capital Investment
11.9 Drivers and Restraints of Biopharmaceutical Market Growth
11.9.1 Drivers
11.9.2 Restraints
Chapter 12: Venture Capital Investment & Biotech
12.1 What is Venture Capital Investment?
12.2 What does VC Offer?
12.3 What Do Venture Capitalists Do?
12.4 Who Are Venture Capitalists?
12.4.1 Banks as Venture Capitalists
12.4.2 Business Angels (Wealthy Individuals) as Venture Capitalists
12.4.3 Corporate or Direct Investors as Venture Capitalists
12.4.4 Government Grants and Governments as Venture Capitalists
12.4.5 Venture Capital Firms
12.4.6 Other Types of Venture Capitalists
12.5 Why Do Biotech Companies Need VC Funding?
12.6 Venture Capital Investment in the US Biotech Market
12.6.1 US VC Investment Now Recovering Following Stockmarket Crash in 2000
12.6.2 329 US Biotech VC Investments Made in 2004, Providing Over $3.8bn
12.6.3 Synta Provides 2004's Largest US Investment Sum With $80m
12.6.4 MPM Capital 2004's Most Active US Biotech VC Firm
12.6.5 Company Expansion Stage is the Most Favourable for VC Investment
12.7 Increase in VC Funding of European Biotech
12.8 PE European Investments in Biotech Followed Similar Trends as in the US
12.9 European PE Biotech Investments are a Small Part of the Funding Market
Chapter 13: Conclusion: Big Pharma Must Invest into Biotech Arena
List of Tables
Table 2.1 Definitions of Selected Biopharmaceuticals
Table 2.2 Summary of Biotechnologies
Table 3.1: Overview to Major Diseases and Selected Orphan Diseases Treated by Biopharmaceuticals, 2005
Table 4.6: Revenue ($m) for Classes of Technology Biopharmaceuticals, 2004
Table 4.1 Biopharmaceutical Revenues ($m) by Technology Class, 2004
Table 4.2: Vaccine Products in 2004 Market
Table 4.3 Monoclonal Antibody Products % Growth Rates, 2004
Table 4.4 Biopharmaceuticals Revenue ($m) by Therapeutic Area, 2004
Table 4.5: Blood Modifiers by Revenue ($m), 2004
Table 4.6: Biopharmaceutical Revenues ($m) in 2003 Top 400 by Drug Type, 2004
Table 4.7 Total Biopharmaceutical Revenues 2003 & 2004
Table 4.8: Top 20 Selling Biopharmaceuticals, 2004
Table 4.9: Revenues of Newcomers to 2004 Biopharmaceuticals Market
Table 5.1: Biopharmaceutical Company Revenues ($m), 2003 & 2004, and 2004 Company Market Share (%)
Table 5.2: Roche Biopharmaceutical Portfolio By Revenue ($m), 2003 and 2004
Table 5.3: GSK Biopharmaceutical Portfolio By Revenue ($m), 2003 and 2004
Table 5.4: Schering Plough Biopharmaceutical Portfolio By Revenue ($m), 2003 and 2004
Table 5.5: Amgen's Product Portfolio By Revenue ($m), 2004
Table 5.6: Amgen Total Revenue ($bn), 2001-2004
Table 6.1: Overview of Biotech Pipeline By Biotechnology Type, 2005
Table 6.2: Arthritis Biopharmaceutical Pipeline, 2005
Table 6.3: MS Biopharmaceutical Pipeline, 2005
Table 6.4: Late Stage Biopharmaceutical Oncology Pipeline
Table 6.5: Late Stage Biopharmaceutical Vaccine Pipeline, 2005
Table 6.6: Blood Disorders Biopharmaceuticals Pipeline, 2005
Table 6.7 Late-Stage Biopharmaceutical Endocrine Pipeline, 2005
Table 6.8 Anti-Infective Biopharmaceutical Pipeline, 2005
Table 6.9 Enzyme Deficiency Disorder Biopharmaceutical Pipeline, 2005
Table 6.10 Late-Stage Biopharmaceutical Ophthalmic Pipeline, 2005
Table 6.11 Late-Stage Biopharmaceutical Others Pipeline, 2005
Table 7.1: Treatment of Blood Disorder by Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.2: Total World Biopharmaceutical Blood Disorder Market Forecast ($m), 2003-2010
Table 7.3 Endocrine Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.4: Total World Biopharmaceutical Endocrine Market Forecast ($m), 2003-2010
Table 7.5: Multiple Sclerosis Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.6: Total World Biopharmaceutical Multiple Sclerosis Market Forecast ($m), 2003-2010
Table 7.7: Oncology Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.8: Total World Biopharmaceutical Oncology Market Forecast ($m), 2003-2010
Table 7.9: Anti-Infective Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.10:Total World Biopharmaceutical Anti-Infectives Market Forecast ($m), 2003-2010
Table 7.11: Enzyme Replacement Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.12: Total World Biopharmaceutical Enzyme Replacement Market Forecast ($m), 2003-2010
Table 7.13: Vaccine Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.14:Total World Biopharmaceutical Vaccine Market Forecast ($m), 2003-2010
Table 7.15: Arthritis Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.16:Total World Biopharmaceutical Arthritis Market Forecast ($m), 2003-2010
Table 7.17: Ophthalmic Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.18: Total World Biopharmaceutical Ophthalmic Market Forecast ($m), 2003-2010
Table 7.19: Other Biopharmaceutical by Revenue ($m), 2003 and 2004
Table 7.20: Total World Biopharmaceutical Other Market Forecast ($m), 2003-2010
Table 7.21: Total Global Biopharmaceutical Market Revenue ($bn) Forecast 2003-2010
Table 8.1: Top 10 Selling Biopharmaceuticals of 2010
Table 8.2: Total Global Biopharmaceutical Market Revenue ($bn) Forecast by Therapeutic Class, 2003-2010
Table 8.3: Market Share of Biopharmaceuticals By Therapeutic Class, 2003 & 2010 Comparison
Table 8.4: Biopharmaceuticals CAGR% By Therapeutic Class, 2003-2010
Table 8.5: Revenues ($bn) of Total Prescriptions By Technology Type 1999-2010
Table 9.1 Biopharmaceuticals Facing Patent Expiry and their Biogeneric Status, 2005
Table 9.2: Key Supporters For Biogenerics And Their Opinions
Table 9.3: Key Opponents Arguments Against Biogenerics
Table 10.1: Biopharmaceuticals Facing Patency Expiry by 2007
Table 10.2 Revenue ($m) Forecast of 6 High Profile Biopharmaceuticals Facing Patency Expiry Before 2007, 2003-2010
Table 11.1 Mode of Administration of 2004's Top 5 Biopharmaceuticals
Table 11.2: Expected Blockbuster Noninjected Insulins From 2005
Table 11.3: Total European IPOs by Country, 2003
Table 12.1: US and European VC Investment ($m) Into Biotech Companies, 1997-2003
Table 12.2: Total US VC Investment ($bn), 1994-2004
Table 12.3: Biopharmaceutical Venture Capital Investments By Quarter, 2003 vs 2004
Table 12.4: Number of Biopharmaceutical Venture Capital Investments By Quarter, 2003 vs 2004
Table 12.5: Top 5 Largest Biotech Investments ($m) by Company, 2004
Table 12.6: Most Active Biotech Venture Capital Firms of 2004
Table 12.7: US VC Investments by Company Stage, 2003-2004
Table 12.8: PE European Investments ($m) in Biotech, 1997-2003
List of Graphs
Graph 2.1:Biopharmaceutical Market Capatilsation ($bn), 1994-2004
Graph 2.2: Total Number of Biotechnology Patents Granted: 1992-2002
Graph 2.3: Number of New Biological FDA Approvals: 1994-2004
Graph 2.4 Biopharmaceuticals Share of Global Prescriptions 1999-2004
Graph 4.1: Global Sales ($m) of Biopharmaceuticals by Technology Class, 2004
Graph 4.2: Global Sales ($m) of Biopharmaceuticals by Therapeutic Area, 2004
Graph 4.3: Total Global Biopharmaceutical Revenue, 2003-2004
Graph 4.4: Top 20 Selling Biopharmaceuticals, 2004
Graph 4.5: Global Procrit/Eprex Sales ($m), 2001-2004
Graph 4.6: Global Risperdal Sales ($m), 2001-2004
Graph 4.7: Global Epogen Sales ($m), 2001-2004
Graph 4.8: Revenues for Newcomers to the Global Biopharmaceutical Market, 2004
Graph 5.1: Biotech Company Revenues ($m), 2003 & 2004
Graph 5.2: Company % Change in Revenue, 2003-2004
Graph 5.3: 2004 Company Newcomers to Biopharmaceuticals Market By Revenue ($m)
Graph 5.4: Amgen Company Revenue ($bn), 2001-2004
Graph 5.5: Amgen Change in Revenue (%), 2002-2004
Graph 6.1: Biopharmaceutical Pipeline by Biotechnology Type, 2005
Graph 6.2: Duration of Therapies of Biotech Pipeline Products in Late-Stage Development, 2003
Graph 7.1: Total World Biopharmaceutical Blood Disorder Market Forecast ($bn), 2003-2010
Graph 7.2: Total World Biopharmaceutical Blood Disorder Market Revenue Growth Forecast (%), 2004-2010
Graph 7.3: Total World Biopharmaceutical Endocrine Market Forecast ($bn), 2003-2010
Graph 7.4: Total World Biopharmaceutical Endocrine Market Revenue Growth Forecast (%), 2004-2010
Graph 7.5: Total World Biopharmaceutical Multiple Sclerosis Market Forecast ($bn), 2003-2010
Graph 7.6: Total World Biopharmaceutical Multiple Sclerosis Market Revenue Growth Forecast (%), 2004-2010
Graph 7.7: Total World Biopharmaceutical Oncology Market Forecast ($bn), 2003-2010
Graph 7.8: Total World Biopharmaceutical Oncology Market Revenue Growth Forecast (%), 2004-2010
Graph 7.9: Total World Biopharmaceutical Anti- Infectives Market Forecast ($bn), 2003-2010
Graph 7.10: Total World Biopharmaceutical Anti-Infectives Market Revenue Growth Forecast (%), 2004-2010
Graph 7.11:Total World Biopharmaceutical Enzyme Replacement Market Forecast ($bn), 2003-2010
Graph 7.12: Total World Biopharmaceutical Enzyme Replacement Market Revenue Growth Forecast (%), 2004-2010
Graph 7.13: Total World Biopharmaceutical Vaccine Market Forecast ($bn), 2003-2010
Graph 7.14: Total World Biopharmaceutical Vaccine Market Revenue Growth Forecast (%), 2004-2010
Graph 7.15: Total World Biopharmaceutical Arthritis Market Forecast ($bn), 2003-2010
Graph 7.16: Total World Biopharmaceutical Arthritis Market Revenue Growth Forecast (%), 2004-2010
Graph 7.17: Total World Biopharmaceutical Ophthalmic Market Forecast ($bn), 2003-2010
Graph 7.18: Total World Biopharmaceutical Ophthalmic Market Revenue Growth Forecast (%), 2004-2010
Graph 7.19: Total World Biopharmaceutical Other Market Forecast ($bn), 2003-2010
Graph 7.20: Total World Biopharmaceutical Other Market Revenue Growth Forecast (%), 2004-2010
Graph 7.21: Total Global Biopharmaceutical Market Revenue Growth (%), 2004-2010
Graph 7.22: Total Global Biopharmaceutical Market Revenue ($bn) Forecast 2003-2010
Graph 8.1: Top-10 Selling Biopharmaceuticals of 2010 ($m)
Graph 8.2: Total Global Biopharmaceutical Market Revenue ($bn) Forecast by Therapeutic Class, 2003-2010
Graph 8.3: % Change of Market Share By Therapeutic Area, 2003 & 2010
Graph 8.4: Biopharmaceuticals CAGR% By Therapeutic Class, 2003-2010
Graph 8.5: Biopharmaceutical Revenue ($bn) of Total Prescriptions, 1999-2010
Graph 10.1 Targets Of Biogeneric Companies By Drug Class
Graph 10.2: Total Revenue ($bn) of Six High Profile Biopharmaceuticals Facing Patent Expiry By 2007, 2003-2010
Graph 10.3: Total Revenue Growth (%) of Six High Profile Biopharmaceuticals Facing Patent Expiry By 2007, 2003-2010
Graph 11.1 Cost of Top Five Selling Biopharmaceuticals of 2004 ($ Per Patient Per Year)
Graph 11.2: Total Financing of Biopharmaceuticals ($bn), 2000-2003
Graph 11.3: Number of Pharmaceutical Alliances Formed By Party, 1997-2001
Graph 11.4: % of Alliances Formed With Licensing, By Party During 2001
Graph 11.5: % of Alliances Formed With Development/Co-Development, By Party During 2001
Graph 11.6: % of Alliances Formed With Research, By Party During 2001
Graph 11.7: Mean FDA Approval Time For New Biopharmaceuticals, 2000-2004
Graph 12.1: US and European VC Investment ($m) Into Biotech Companies, 1997-2003
Graph 12.2: Total US VC Investment ($bn), 1994-2004
Graph 12.3: % Change From Previous Year of Total US VC Investment, 1995- 2004
Graph 12.4: Total Biotech VC Investments ($m) By Quarter, 2003-2004
Graph 12.5: % Change of Biotech VC Investments By Quarter, 2003-2004
Graph 12.6: Number of Biotech VC Investments By Quarter, 2003 -2004
Graph 12.7: % Change of Number of Biotech VC Investments By Quarter, 2003 -2004
Graph 12.8: PE European Investments ($m) in Biotech, 1997-2003
Graph 12.9: % Change of PE European Investments ($m) in Biotech, 1998-2003
List of Charts
Chart 4.1: Biopharmaceutical Market Share (%) by Class, 2004
Chart 4.2: Biopharmaceutical Market Share (%) by Therapeutic Class, 2004
Chart 4.3 Top 20 Selling Biologics Share (%) of Total Biopharmaceuticals Market
Chart 4.4: Global Market Share (%) for the Top 3 Selling Biologics, 2004
Chart 5.1: 2004 Market Share (%) By Company
Chart 6.1: Pipeline share (%) of Biopharmaceuticals Duration of Therapy, 2003
Chart 11.1: Biopharmaceutical Industry Financing By Source, 2003
Chart 8.1: Market Share of the Top-10 Selling Biopharmaceuticals (%), 2010
Chart 8.2: Biopharmaceutical Therapeutic Class Market Share (%), 2003
Chart 8.3: Biopharmaceutical Therapeutic Class Market Share (%), 2010
Chart 10.1: Six High Profile Biopharmaceuticals Revenue Share (%) of Total Biopharmaceuticals Facing Patency Expiry By 2007, 2004
Chart 12.1: US VC Investments in Biotech by Company Stage, 2004
Other users found this report page using the following search terms:
biotech
biotechnology
antibodies
therapeutic proteins
rnai
gene therapy
vaccine
market
biotech
world
biotechnology
biopharmaceuticals
biopharmaceutical
2005
graph
2007
forecast
If you can't find a report that meets your needs contact LeadDiscovery . We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.
